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Abstract
Background: We previously reported a high prevalence (22.3%) of gestational diabetes mellitus
(GDM) in a large group of Sardinian women, in contrast with the prevalence of Type 2 diabetes.
Sardinia has an unusual distribution of haplotypes and genotypes, with the highest population
frequency of HLA DR3 in the world, and after Finland, the highest prevalence of Type 1 diabetes
and Autoimmune-related Diseases. In this study we preliminarily tested the prevalence of
serological markers of Type 1 diabetes in a group of Sardinian GDM patients.
Methods: We determined glutamic decarboxylase antibodies (anti-GAD65), protein tyrosine
phosphatase ICA 512 (IA2) antibodies (anti-IA2), and IAA in 62 GDM patients, and in 56 controls
with matching age, gestational age and parity.
Results: We found a high prevalence and very unusual distribution of antibodies in GDM patients
(38.8%), the anti-IA2 being the most frequent antibody. Out of all our GDM patients, 38.8% (24 of
62) were positive for at least one antibody. Anti-IA2 was present in 29.0 % (18 out of 62) vs. 7.1%
(4 out of 56) in the controls (P < 0.001). IAA was present in 14.5% (9 out of 62) of our GDM
patients, and absent in the control subjects (P < 0.001). Anti-GAD65 was also present in GDM
patients, with a prevalence of 3.2% (2 out of 62) while it was absent in the control group (P = NS).
Pre-gestational weight was significantly lower (57.78 ± 9.8 vs 65.9 ± 17.3 P = 0.04) in auto-
antibodies- positive GDM patients.
Conclusion: These results are in contrast with the very low prevalence of all antibodies reported
in Italy. If confirmed, they could indicate that a large proportion of GDM patients in Sardinia have
an autoimmune origin, in accordance with the high prevalence of Type 1 diabetes.
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Background
Gestational diabetes mellitus (GDM) is defined as "carbo-
hydrate intolerance of variable severity with onset or first
recognition during pregnancy" [1] and affects 1–14% of
all pregnancies, depending on the population studied, the
diagnostic test and its glycemic cut-off. Its prevalence mir-
rors that of Type 2 diabetes mellitus [2,3].
The prevalence of GDM in Italy was reported to be 2.3–
10% [4,5]. A recent study of ours found [6] a surprisingly
high prevalence (22.3%) of GDM in a large group of Sar-
dinian women, in contrast with the prevalence of Type 2
diabetes in Sardinia. In fact, the prevalence of Type 2 dia-
betes in Sardinia is similar to that of other non high risk
populations, while after Finland, it has the highest preva-
lence in the world of Type 1 diabetes mellitus and Type 1
diabetes- related Autoimmune Diseases, such as Multiple
Sclerosis, Celiac Disease, Autoimmune Thyroid Disease
[7-11]. Compared to other Caucasian populations Sar-
dinia has an unusual distribution of haplotypes and gen-
otypes, with the highest population frequency of HLA
DR3 in the world, which partially explains the high inci-
dence of Type 1 diabetes [12,13]. For these reasons Sar-
dinia is an ideal population to study environmental,
genetic and immunological factors involved in the patho-
genesis of different diseases.
Type 1 diabetes results from a chronic autoimmune
destruction of the insulin-secreting pancreatic beta cells,
probably initiated by exposure of a genetically susceptible
host to an environmental agent. During the preclinical
phase, this autoimmune process is marked by circulating
auto-antibodies against pancreatic islets or against beta
cell antigens, such as islet cell antibodies (ICA), glutamic
decarboxylase antibodies (GADA, recently replaced by the
anti-GAD65, more specific for Type 1 diabetes), protein
tyrosine phosphatase ICA 512 (IA2) antibodies (anti-
IA2), and auto-antibodies to Insulin (IAA). These auto-
antibodies (Diabetes-Related Auto-antibodies, DRAs) are
present years before the onset of Type 1 diabetes and prior
to any clinical symptoms. Preliminary studies have shown
that the progression of Type 1 diabetes in Sardinia is also
accompanied by an increased frequency of a combination
of ICA with GAD or IA2 antibodies, or both [14].
A variable percentage of women with GDM are reported
to be positive for the DRAs [15-23]. In these patients ges-
tational diabetes is caused by the destruction of β-pancre-
atic cells by an auto-immune process as a result of
interaction between genetic and environmental factors, in
a similar way to what occurs in Type 1 diabetes, which
leads to an insulin deficiency. The prevalence of DARs
usually mirrors the prevalence of Type 1 diabetes outside
pregnancy.
The prevalence of GAD antibodies in GDM patients has
been shown to range between 0 and 38 %, that of ICAs
between 1 and 38 %, that of IAA between 0 and 18%, and
that of anti-IA2 between 0 and 6.2%. In Italy the preva-
lence of DARs in GDM patients has been reported to be
very low [18,19]. Besides the different methods of study
and laboratory procedures employed, the heterogeneity of
the results is due to the different genetic and environmen-
tal background of each population, which determines the
susceptibility to auto-immunity. Today auto-immune
GDM is considered a heterogeneous disorder, which may
result in various types of expression of the immune reac-
tivity against the β-cells [23].
In women with GDM DRAs have been found to have a
high positive predictive value for Type 1 diabetes after
pregnancy [20-22,24]. GDM patients with positivity for
DRAs can rapidly develop Type 1 diabetes after pregnancy
and have peculiar characteristics. They are often slim,
younger that those who develop Type 2 diabetes and have,
as in Type 1 diabetes, an increased prevalence of HLA DR3
or DR4-DQ8 haplotypes. In addition, the majority of
these women require insulin to treat their diabetes during
pregnancy [21,24].
The frequency of DRAs in Sardinian women with GDM is
still unknown. Considering the peculiarity of the Sardin-
ian population, the high prevalence of Type 1 diabetes
and the high prevalence of GDM on the island, it may be
theorize that a large proportion of our GDM could have
an autoimmune origin. Such a hypothesis needs to be
confirmed by a large study assessing the prevalence of
DRAs in a large GDM population, and by a follow-up
study to verify their predictive value for the development
of Type 1 diabetes. Nevertheless, on these grounds, we
attempted to test this hypothesis in a pilot study.
Methods
Anti-GAD65, anti-IA2, and IAA were determined in 62
GDM patients and in 56 controls with matching age, ges-
tational age and parity, consecutively referred to our
Obstetric Diagnostic Centre. The purpose and nature of
the study were explained to all subjects, and their consent
was obtained before their participation. The local Institu-
tional Review Board approved the study.
All patients were Sardinian of Sardinian descent. None of
them had a history of GDM, Type 1 or Type 2 diabetes.
Diagnosis of GDM was made by a 100-g Oral Glucose Tol-
erance Test (OGTT) on the ADA's recommendation (Car-
penter and Coustan criteria: two or more values meeting
or exceeding the following: fasting: 95 mg/dl, 1 h: 180
mg/dl, 2 h: 155 mg/dl, 3 h: 140 mg/dl) [25]. The patients'
characteristics of GDM and control women are reported in
Table 1. A venous blood sample was taken from allReproductive Biology and Endocrinology 2008, 6:24 http://www.rbej.com/content/6/1/24
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women between 17 and 41 weeks of gestational age, and
none of them were taking insulin when the auto-antibod-
ies were determined. Serum was separated by centrifuga-
tion, and kept at -20°C. Anti- GAD65, anti-IA2 and IAA,
were determined by Radioligand Assay (Medipan GMBH-
Berlin, Germany). Highly purified human recombinant
antigens labeled with 125I was used to identify anti-
GAD65 and anti-IA2. The cut-off limit for positivity was
0.9 and 0.75 U/ml for anti-GAD65 and anti-IA2, respec-
tively. Highly purified human 125I-(A14) mono-iodinated
insulin was used for the IAA determination. The cut-off
limit for its positivity was 1 U/ml.
After diagnosis, GDM patients were instructed to follow a
moderately hypocaloric regimen (30 Kcal/kg ideal body
weight) and trained to self-monitor their blood glucose,
according to the ADA's recommendations [25]. Their gly-
cemic control and the ultrasound monitoring of foetal
growth were followed in our Outpatient Centre until
delivery. Insulin therapy was started if they reported 2-
hours postprandial glycemic levels ≥ 120 mg/dl and/or
fasting levels ≥ 95 mg/dl, according with ADA[25].
Statistics
The prevalence of antibody-positive subjects in the GDM
group was compared to those of the control group with a
Chi-Square test. Statistical differences between continu-
ous variables were analysed with a Student t-test. All anal-
yses were performed using XLSTAT v 2007 software. For
all analyses, P < 0.05 was considered to be statistically sig-
nificant.
Results
GDM patients differed from control patients only in Body
Mass Index (BMI), significantly higher in GDM patients
(24.1 ± 4.6 kg/m2 vs 22.0 ± 2.7 kg/m2, P = 0.008).
The prevalence of DRAs in GDM patients and controls are
shown in Table 2. On the whole, 38.8% (24 out of 62) of
the GDM patients were positive for at least one antibody:
anti-IA2 was present in 29.0% (18 out of 62) of our GDM
patients vs. 7.1% (4 out of 56, P < 0.001), while IAA was
found positive in 14.5% of them (9 out of 62) and absent
in the control subjects (P < 0.001). Anti-GAD65 was also
present in our GDM patients, with a prevalence of 3.2% (2
out of 62) while it was absent in the control group (P =
NS). Five GDM patients (8%) in the whole group were
positive for 2 antibodies, which were IAA + anti-IA2 for
four of them, and IAA+ anti-GAD for one volunteer
(1.6%).
Differences between auto-antibodies-positive and -nega-
tive GDM patients are shown in Table 3. No differences
were shown in age, BMI, requirement of insulin therapy,
and neonatal birth weight. Pre-gestational weight was sig-
nificantly lower (57.78 ± 9.8 vs. 65.9 ± 17.3 P = 0.04) in
auto-antibodies-positive patients.
Discussion
Screening, diagnosis and treatment of GDM are very
important in order to prevent related complications.
Moreover, GDM identifies women who are at risk of
developing diabetes later in life, usually Type 2 diabetes
and less frequently Type 1 diabetes [20-22]. An early diag-
nosis of Type 1 diabetes is shown to preserve endogenous
insulin secretion and to decrease the frequency of micro-
vascular complications [26]. For these reasons, detecting
during pregnancy the markers that identify individuals at
risk of developing Type 1 diabetes in the future could be
very important for public health in regions where there is
a high prevalence of this disease. We focused our attention
on previous reported high prevalence of GDM in a large
group of Sardinian women [6] and the well-known high
prevalence of Type 1 diabetes in Sardinia [7]. Our findings
on DRAs in GDM women are very different from what has
been reported with regard to Italy. Two Italian studies
[18,19] reported a very low prevalence of all auto-anti-
Table 1: Clinical characteristics of patients with GDM and 
control subjects
GDM group Control group P
N6 2 5 6
Age (years) 34.0 ± 4.4 32.5 ± 5.0 -
Parity 0.4 ± 0.7 0.5 ± 0.6 -
Gestational Age (weeks) 26.3 ± 4.6 25.5 ± 5.0 -
BMI (kg/m2) 24.1 ± 4.6 22.0 ± 2.7 0.008
Data are means ± SD
Table 2: Prevalence of auto-antibodies in GDM patients and control subjects
Autoantibody GDM group (N = 62) 
N (%)
Control group (N = 56) 
N (%)
P
Anti-GAD65 2 (3.2) 0 (0) -
Anti -IA2 18 (29.0) 4 (7.1) < 0.001
IAA 9 (14.5) 0 (0) < 0.001
TOTAL 24 (38.8) 4 (7.1) < 0.001
2 antibodies 5 (8) 0 (0) 0.005Reproductive Biology and Endocrinology 2008, 6:24 http://www.rbej.com/content/6/1/24
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bodies in GDM patients. Specifically, anti-IA2 was com-
pletely absent in the patients screened in both studies,
whereas anti-GAD was absent in one study [18] and
present in 1.4% of GDM patients in the other [19]. IAA
was tested only in one study [18], with a reported preva-
lence of 3%. The low antibody prevalence is likely to be
related to the low incidence of Type 1 diabetes in the
Northern Italy, which is one of the lowest in Europe. Thus,
although little difference could be ascertained between
our results and those of other Italian studies regarding the
prevalence of GAD, the greatest difference regards the
anti-IA2 and IAA values. Indeed, anti-IA2 was the most
frequent antibody (present in 29% of our patients), while
it was in fact absent in other Italian study groups. The dif-
ferent expression of DRAs in different geographic areas
could be related to different genetic backgrounds, result-
ing in a different expression of the immune reactivity.
Indeed, HLA genotypes appear to have a modifying influ-
ence on the expression of diabetes associated auto-anti-
bodies. Anti-IA2 positively correlated with DQ8 and/or
DR4/DQB1*0201 and was negatively associated with
DR3/DQB1*0201 [27]. Similarly, IAAs and ICAs are
found with a higher frequency in individuals positive for
DR4 and DQ8, while anti- GAD65 is more commonly
found in Type 1 diabetic patients with DR3 and or
DQB1*0201 haplotypes [27]. It has been suggested that
the DR3-associated anti GAD65 response is a marker of
general autoimmunity, whereas the DR4-associated anti-
IA2 response is a more specific marker of β-cell destruc-
tion [27]. However these suggestions seem to be in con-
trast with our higher prevalence of anti-IA2 and the more
common Sardinian haplotype HLA DR3. Unfortunately
no study which correlates genetic and autoimmune mark-
ers of Type 1 diabetes in the Sardinian population, has
ever been conducted to date. Moreover, the only study car-
ried out in schoolchildren and newborns did not show a
higher frequency of any specific autoantibody [14].
It may be hypothesized that our DRAs – positive patients
could have a condition known as LADA (Latent Autoim-
mune Diabetes in Adults). However, ICA and GADAs are
also common in LADA, but both anti-IA2 and IAA are
much less common in LADA than Type 1 diabetes [28].
Anti-IA2 is present in the majority of individuals with new
onset Type 1 diabetes and, in the pre-diabetic phase of the
disease, its appearance seems to be correlated with the
rapid progression to overt Type 1 diabetes [24,29,30].
Anti-IA2 was also present in 7.1% of our control subjects,
but this is in agreement with findings by Jarvela [18,21],
who reported variable percents of positivity for all DRAs
in the control group. Moreover, it must not be forgotten
that these antibodies are first of all markers of Type 1 dia-
betes and that they can in theory be present in any indi-
vidual, independently of the presence GDM, in particular
in areas where there is a high prevalence of Type 1 diabe-
tes. Nevertheless, the meaning of positivity of this anti-
body on GDM patients remains to be clarified because in
two studies [20,21], the anti-IA2 did not represent an
independent risk factor for the development of Type 1 dia-
betes postpartum, whereas anti-GAD and ICA did. How-
ever, when found positive together with anti-GAD, it
increased the screening sensitivity of anti-GAD from 63%
to 75% [20].
IAA often precedes other autoimmune markers [27], and
this led to the hypothesis that insulin may be an auto-
antigen in Type 1 diabetes, which may play a role early in
the pathogenic process. For this antibody too, like the
anti-IA2, it is unknown whether its presence in GDM
could be useful, because in the Finnish study [21], none
of the women with previous GDM who developed Type 1
diabetes tested positive for IAA.
It is interesting that though the BMI of GDM patients was
higher than controls, as would be expected since being
overweight is a well known risk factor for GDM [25], the
pre-gestational weight was significantly lower in DRAs-
positive patients. This finding is in line with other pub-
lished studies [17], in that DRAs-positive patients are usu-
ally slim, and could be consistent with a future
development of Type 1 diabetes rather than Type 2, since
the latter is usually associated with obesity. In contrast,
our DRAs-positives patients are not younger than the
DRAs-negatives ones, as shown for the patients affected by
GDM who develop Type 1 diabetes after pregnancy [21].
Table 3: Characteristics of GDM auto-antibodies -positive and -negative GDM patients
Ab- positive 
(N = 24)
Ab- negative 
(N = 38)
P
Mean age (yrs, mean ± SD) 34.7 ± 4.4 33.6 ± 4.5 0.36
Pre-gestational weight (Kg, mean ± SD) 57.78 ± 9.8 65.9 ± 17.3 0.04
BMI 22.7 ± 3.5 24.9 ± 5.1 0.09
Parity (N, mean ± SD) 0.28 ± 0.78 0.51 ± 0.74 0.27
Insulin therapy (N, %) 6 (25%) 6 (15.7%) 0.3
Birth weight (Kg) 3 ± 0.6 3.1 ± 0.6 0.6Reproductive Biology and Endocrinology 2008, 6:24 http://www.rbej.com/content/6/1/24
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The use of insulin for the treatment of GDM, which
reflects the severity of the disease, was shown to be an
independent risk factor for the occurrence of postpartum
Type 1 diabetes [20,21]. We could not show a significant
difference in the need for insulin therapy of DRAs-positive
patients, as could be hypothesized if an immune-medi-
ated destruction of pancreatic β-cells had occurred. How-
ever, a difference exists (25% vs. 15% in Ab-negative
patients) which should be confirmed in a larger group of
patients, in order to have statistical significance. Likewise,
a more severe disease could not be shown in the group
characterized by a greater neonatal birth weight, although
this could signify that our protocol of monitoring and
therapy was effective.
Parity was chosen as a comparison parameter, since other
studies [20,24] found that women with one or more pre-
vious pregnancies had a higher risk for both Type 1 and
Type 2 diabetes, but no difference was found in parity
between DRas-positive and DRas-negative patients.
Conclusion
Our findings are in contrast with the very low prevalence
of all antibodies reported in Italy, and could be consistent
with the peculiarity of the genetic and immunological fea-
tures of the Sardinian population. If confirmed, they
could indicate that a large proportion of GDM patients in
Sardinia have an autoimmune origin, in accordance with
the high prevalence of Type 1 diabetes.
The screening for auto-antibodies in pregnant women
with GDM in populations at high risk for Type 1 diabetes
has been recommended to allow an early diagnosis and,
consequently, an appropriate therapy [20].
However, our results need further, extensive follow-up
studies on a larger obstetric population, to verify whether
or not our DRAs-positive patients are really at risk of
developing Type 1 diabetes. A genetic characterization of
DRAs-positive GDM patients would be also opportune.
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